glp 1 patents Patent and Innovation Trends in GLP-1 and Weight Loss Drugs (2020–2025) GLP-1 patents and Africa: The

or call us at (504) 267-4549 In-Person WL Contact Form *Chronos Body Health & Wellness follows all applicable FDA, DEA, and Louisiana state regulations

Recent investigations by UK and U.S

Retatrutide, a novel triple receptor agonist targeting glucagon-like peptide-1 (GLP-1), Glucose-Dependent Insulinotropic Polypeptide (GIP), and glucagon receptors, represents a groundbreaking advancement in obesity and T2DM pharmacotherapy

Collage by Diana Connolly

Oral semaglutide (Rybelsus): This form contains an absorption enhancer called SNAC to help the medication work

Reason for caution: Some formulations are not studied in severe renal disease, and significant vomiting or diarrhea from side effects could further harm kidney function